Nectar Lifesciences share price
NSE: NECLIFEBSE: 532649Pharmaceuticals & BiotechnologySmall Cap
Last close ₹10.28down ₹0.48 (4.46%)BSE ₹10.33
Share price at the NSE close on 23 Oct 2026. Previous close ₹10.76.
52-week range of traded prices to 23 Oct 2026
₹9.30Low, 30 Mar 2026₹22.40High, 23 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹200 Cr2,221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 May 2026
- 0.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- −31.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹171 crore of one-off items, the largest of them in the quarter to Sep 2025.
- −9.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- −15.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,01,72181.0% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 14 Aug
- Revenue
- ₹0.01 Cr
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹15 CrQuarter to Mar 2026: −₹68 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −1,06,191.0%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 4 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2018, GST replaced excise duty on 1 Jul 2017, and revenue before that day includes the duty. From the year to Mar 2026, the company reports a discontinued business.
| ₹ crore | Sep 2024Filed 14 Nov | Dec 2024Filed 31 Jan | Mar 2025Filed 8 Jul | Jun 2025Filed 14 Aug | Sep 2025Filed 14 Nov | Dec 2025Filed 23 Jan | Mar 2026Filed 30 May | Jun 2026Filed 14 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 428 | 455 | 431 | 281 | 5 | – | – | 0 |
| Net profit | 6 | 8 | −130 | −63 | −176 | 14 | −68 | −15 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 1.3% | 1.7% | −30.2% | −22.5% | – | – | – | −1,06,191.0% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share. Net margin is left blank for Sep 2025: the profit includes the result of a business the company has discontinued, which the revenue does not, so the two make no margin.
The quarters either side of a change of basis do not compare. From the quarter to Sep 2025, the company reports a discontinued business.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical Business Segment, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: loss, last twelve months. Not shown, EV/EBITDA: operating loss, last twelve months. Its history crosses a change of basis in the accounts in the years to Mar 2018 and Mar 2026: days before it are of the company before the change.PE ratio and valuation history
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 18% of 1,879 trading days since Nov 2018.
LowestHighest
Its median0.5Industry median2.9
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 51% of 2,480 trading days over the last 10 years.
LowestHighest
Its median0.00%Industry median0.53%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −59.5% | – | – | 0.0% |
| 3 years | −16.5% | – | – | 0.0% |
| 5 years | −12.9% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Nectar Lifesciences in market cap.
Nectar Lifesciences is not on the chart: it has no P/E today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Everest OrganicsEVERESTO | 222 | 42.2 | 2.9 | 13.8 | +5.5% | −15.2% | 7.2% | 10.5% | 0.00% |
 Gennex LaboratoriesGENNEX | 211 | 11.5 | 0.9 | 9.1 | +24.1% | +7.3% | 9.0% | 7.0% | 0.00% |
 Sat Kartar LifeSATKARTAR | 206 | 12.0 | 3.0 | – | – | – | 28.7% | – | 0.54% |
 Accretion PharmaceuticalsACCPL | 202 | 20.9 | 3.7 | – | +56.2% | +42.3% | 27.6% | – | 0.00% |
 Accretion NutravedaANL | 198 | 39.0 | 5.6 | – | – | – | 14.3% | – | 0.00% |
| Bio Medica LaboratoriesBMLL | 188 | 16.1 | – | – | – | – | 44.2% | – | 0.00% |
 Sanjivani ParanteralSANJIVIN | 188 | – | 3.9 | 13.5 | +13.2% | – | – | 20.2% | 0.00% |
 Coral LaboratoriesCORALAB | 177 | 9.2 | 0.8 | 5.8 | −5.4% | +7.2% | 9.4% | 7.6% | 0.40% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹0.05 a share, in 4 years, the latest the year to Mar 2020.
| Ex-date | Type | Per share |
|---|---|---|
| 11 Sep 2020 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.05 |
| 19 Sep 2019 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.05 |
| 19 Sep 2018 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.05 |
| 20 Sep 2017 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.05 |
| 22 Sep 2016 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.10 |
| 22 Sep 2015 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.10 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
Aug 2026
Nectar Lifesciences share price by year
Each calendar year to 2025.Nectar Lifesciences share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 19.41 | −50.2% | 40.90 | 13.10 |
| 2024 | 38.98 | +21.2% | 53.92 | 28.06 |
| 2023 | 32.15 | +31.0% | 34.15 | 14.65 |
| 2022 | 24.55 | −8.4% | 36.70 | 19.90 |
| 2021 | 26.80 | +12.1% | 46.50 | 18.60 |
| 2020 | 23.90 | +96.7% | 27.35 | 7.45 |
| 2019 | 12.15 | −41.2% | 20.65 | 11.20 |
| 2018 | 20.65 | −47.0% | 40.50 | 18.90 |
| 2017 | 38.95 | +18.0% | 41.25 | 25.30 |
| 2016 | 33.00 | −39.1% | 55.60 | 28.65 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 11.08 | 11.08 | 10.23 | 10.28 | 10.31 | 1,01,721 | 81.0% |
| 22 Oct 2026 | 11.29 | 11.50 | 10.73 | 10.76 | 11.15 | 2,34,578 | 80.9% |
| 21 Oct 2026 | 11.61 | 11.61 | 11.07 | 11.29 | 11.41 | 6,66,210 | 56.5% |
| 19 Oct 2026 | 10.90 | 11.06 | 10.85 | 11.06 | 11.05 | 1,64,476 | 97.8% |
| 16 Oct 2026 | 10.20 | 10.54 | 10.10 | 10.54 | 10.48 | 1,71,958 | 81.6% |
| 15 Oct 2026 | 10.10 | 10.30 | 10.01 | 10.04 | 10.10 | 97,751 | 76.4% |
| 14 Oct 2026 | 10.25 | 10.35 | 10.05 | 10.16 | 10.15 | 56,290 | 78.8% |
| 13 Oct 2026 | 10.35 | 10.35 | 10.00 | 10.15 | 10.10 | 1,04,351 | 75.0% |
| 12 Oct 2026 | 10.40 | 10.40 | 10.08 | 10.14 | 10.17 | 1,37,664 | 76.8% |
| 9 Oct 2026 | 10.26 | 10.59 | 10.03 | 10.13 | 10.20 | 2,06,786 | 77.2% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 8 Jul 2025 | Price move | – | Between two trading sessions the price moved by a fifth or more. The company made an announcement in time for trading that day or the trading day before. Not adjusted for. |
| 12 Nov 2008 | Split | 0.1000 | Each share became 10. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- Legal name
- Nectar Lifesciences Limited
- NSE symbol
- NECLIFE
- BSE code
- 532649
- ISIN
- INE023H01027
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jul 2005
- Face value
- ₹1
- CIN
- L24232PB1995PLC016664
- Corporate identity number, the registrar of companies' code for it